ライフサイエンスコーパス: radium-223

1 y (docetaxel), abiraterone, enzalutamide, or radium 223.

2 MPCA study and before regulatory approval of radium-223.

3 docetaxel use on the efficacy and safety of radium-223.

4 s performed before crossover from placebo to radium-223.

5 cetaxel, cabazitaxel), radiopharmaceuticals (radium 223, (177)Lu-prostate-specific membrane antigen [

6 The targeted alpha therapy radium-223 ((223)Ra) can prolong survival in men with ca

7 ing exposure to alpha-particles emitted from radium-223 ((223)Ra) using 28 genetically diverse human

8 d care excluded chemotherapy, immunotherapy, radium-223 ((223)Ra), and investigational drugs.

9 terone acetate/prednisone, enzalutamide, and radium-223 ((223)Ra; for men with predominantly bone met

10 696 patients received one or more doses of radium-223; 403 (58%) of these patients had all six plan

11 response system to receive six injections of radium-223 (50 kBq/kg intravenously) or matching placebo

12 receive either six intravenous injections of radium-223 (50 kBq/kg) or matching placebo; one injectio

13 Patients received intravenous injections of radium-223, 50 kBq/kg (current recommendation 55 kBq/kg

14 receive up to six intravenous injections of radium-223 (55 kBq/kg) or matching placebo once every 4

15 PCA trial showed that radium-223 dichloride (radium-223), a targeted alpha-emitter, improved overall

16 Radium-223 dichloride (radium-223), an alpha emitter, selectively targets bone

17 Radium-223, an alpha-emitting radionuclide still under r

18 614 (67%) were randomly assigned to receive radium-223 and 307 (33%) placebo.

19 mia and neutropenia were similar between the radium-223 and placebo groups within both docetaxel subg

20 Radium-223 and sipuleucel-T also are options.

21 azitaxel, abiraterone acetate, enzalutamide, radium-223, and sipuleucel-T has increased the number of

22 amide, darolutamide, docetaxel, cabazitaxel, radium-223, and sipuleucel-T have been approved for adva

23 We assessed the efficacy and safety of radium-223 as compared with placebo, in addition to the

24 terim analysis, which involved 809 patients, radium-223, as compared with placebo, significantly impr

25 in a 2:1 ratio, to receive six injections of radium-223 (at a dose of 50 kBq per kilogram of body wei

26 Our findings show that radium-223 can be safely combined with abiraterone or en

27 We assessed the effect of radium-223 compared with placebo in patients with castra

28 The benefit of radium-223 compared with placebo was seen in both doceta

29 Background: Radium-223 dichloride ([(223)Ra]RaCl2) is the first appr

30 hypothesized the BM-targeting alpha-emitter radium-223 dichloride (Ra223) could target subclinical b

31 Radium-223 dichloride (radium-223) selectively targets b

32 ignificantly longer in patients treated with radium-223 dichloride (radium-223) than in patients trea

33 from the phase 3 ALSYMPCA trial showed that radium-223 dichloride (radium-223), a targeted alpha-emi

34 Radium-223 dichloride (radium-223), an alpha emitter, se

35 ncreasing with the adoption into practice of radium-223 dichloride for the treatment of bone metastas

36 itionally, the radioactive therapeutic agent radium-223 dichloride has been recently approved in pati

37 (177)Lu-PSMA RLT in 154 (32%) patients, and radium-223 dichloride in 18 (4%) patients.

38 bitors, lutetium-177 ((177)Lu) PSMA RLT, and radium-223 dichloride.

39 Investigations involving alpha-emitting radium-223, endothelin-A receptor antagonists atrasentan

40 deaths occurred in two (1%) patients in the radium-223 group (acute myocardial infarction and inters

41 occurred in 202 (33%) of 614 patients in the radium-223 group and 116 (38%) of 307 patients in the pl

42 ebo group) and 395 (43%) had not (262 in the radium-223 group and 133 in the placebo group).

43 events occurred in 160 (41%) patients in the radium-223 group and 155 (39%) in the placebo group.

44 ved previous docetaxel treatment (352 in the radium-223 group and 174 in the placebo group) and 395 (

45 al was 22.3 months (95% CI 20.4-24.8) in the radium-223 group and 26.0 months (21.8-28.3) in the plac

46 occurred in 112 (29%) of 392 patients in the radium-223 group and 45 (11%) of 394 patients in the pla

47 Feb 15, 2018), 196 (49%) of 401 patients in radium-223 group had had at least one symptomatic skelet

48 more fractures and deaths were noted in the radium-223 group than in the placebo group (in an unplan

49 were hypertension (43 [11%] patients in the radium-223 group vs 52 [13%] patients in the placebo gro

50 ficacy at the prespecified interim analysis, radium-223 improved overall survival.

51 Radium-223 improves overall survival and delays the onse

52 of skeletal-related events (SREs), but only radium-223 improves survival.

53 acetate plus prednisone or prednisolone and radium-223 in such patients.

54 Radium 223 is recommended for patients with symptomatic

55 Radium-223 is effective and well tolerated in patients w

56 ated events, whereas the radiopharmaceutical radium-223 is shown to reduce the incidence of symptomat

57 .1%] with some postsecondary education), and radium 223 (n = 21) (mean [SD] age, 76.4 [7.2] years; 17

58 6 patients were randomly assigned to receive radium-223 (n=401) or placebo (n=405) in addition to abi

59 oc analysis), but all patients had completed radium-223 or placebo before this date.

60 ednisolone 5 mg twice daily during and after radium-223 or placebo treatment.

61 val was also longer in patients who received radium-223 plus abiraterone, enzalutamide, or both (medi

62 months, 12-16), and in patients who received radium-223 plus denosumab (median NA, 15 months-NA) than

63 Radium-223 prolonged median overall survival compared wi

64 of enzalutamide and 6 monthly injections of radium-223 (Ra223) in patients with metastatic castratio

65 Denosumab and radium-223 reduce the risk of skeletal-related events (S

66 Radium-223 dichloride (radium-223) selectively targets bone metastases with hig

67 Radium-223 should be considered as a treatment option fo

68 nalysis involving 921 patients confirmed the radium-223 survival benefit (median, 14.9 months vs. 11.

69 incidence of grade 3-4 thrombocytopenia with radium-223 than with placebo (31 [9%] of 347 patients vs

70 t symptomatic skeletal event was longer with radium-223 than with placebo (median 15.6 months [95% CI

71 patients treated with radium-223 dichloride (radium-223) than in patients treated with placebo.

72 The addition of radium-223 to abiraterone acetate plus prednisone or pre

73 investigated safety and overall survival in radium-223 treated patients in an early access programme

74 Radium-223 treatment did not seem to significantly reduc

75 ated the effect of previous docetaxel use on radium-223 treatment for the primary endpoint of overall

76 symptomatic skeletal event was reduced with radium-223 versus placebo in patients with previous doce

77 deaths had occurred, assessed the effect of radium-223 versus placebo on survival.

78 Radium-223 was associated with low myelosuppression rate

79 , enzalutamide, or radium Ra 223 dichloride (radium 223) were enrolled between July 1, 2015, and Dece

80 15 months-NA) than in patients who received radium-223 without denosumab (median 13 months, 12-NA).